Controlled Release of Hydrogen-Carrying Perfluorocarbons for Ischemia Myocardium-Targeting 19 F MRI-Guided Reperfusion Injury Therapy.
Chaoqun Nie, Rong A, Jing Wang, Shuang Pan, Rentong Zou, Bin Wang, Shuiqing Xi, Xiaojian Hong, Meifang Zhou, Haoyu Wang, Mengshu Yu, Lina Wu, Xilin Sun, Wei Yang · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In mice, as shown in Figure 2h, PFOB NEs have an excellent hydrogen‐carrying capacity of ≈ 6 mM, which is about eight times higher than that of water. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in mice. As shown in Figure 2h, PFOB NEs have an excellent hydrogen‐carrying capacity of ≈ 6 mM, which is about eight times higher than that of water.
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Hydrogen gas is recently proven to have anti-oxidative and anti-inflammation effects on ischemia-reperfusion injury. However, the efficacy of hydrogen therapy is limited by the efficiency of hydrogen storage, targeted delivery, and controlled release. In this study, H₂ -PFOB nanoemulsions (NEs) is developed with high hydrogen loading capacity for targeted ischemic myocardium precision therapy. As shown in Figure 2h, PFOB NEs have an excellent hydrogen‐carrying capacity of ≈ 6 mM, which is about eight times higher than that of water. The authors concluded that numbers indicate the percentage of FITC+ cells expressing the specific cell marker. Figure 1 Schematic illustration of hydrogen therapy strategy and mechanisms of enhanced therapeutic effect of H₂ ‐PFOB NEs combined with LIFU.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment.
Limitations and Safety
Reported limitations: However, the efficacy of hydrogen therapy is limited by the efficiency of hydrogen storage, targeted delivery, and controlled release.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.